---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Humanistic burden and health-related quality of life"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Humanistic burden and health-related quality of life. Topics: Company description of the humanistic burden of tumor hyperinsulinism (insulinoma and NICTH), Functional status and hospice consideration in refractory tumor hyperinsulinism (malignant insulin-secreting tumors), Impaired quality of life with residual hypoglycemia after insulinoma treatment (Japanese nationwide survey), and Long-term 15D health-related quality of life after curative surgery for insulinoma (Finland). 4 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/humanistic-burden-and-health-related-quality-of-life"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Humanistic burden and health-related quality of life

<a id="heading-2.2.1.8.1"></a>

## 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

### Company description of the humanistic burden of tumor hyperinsulinism (insulinoma and NICTH)

> “Resulting hypoglycemia is often severe and may have serious adverse outcomes”
> “High morbidity and mortality rates”
> “Significant adverse impact on patient quality of life”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-2.2.1.8.1-2"></a>

### Functional status and hospice consideration in refractory tumor hyperinsulinism (malignant insulin-secreting tumors)

> “current standard-of-care therapies to reduce hypoglycemia often fail to achieve sustained glycemic stability and are associated with high morbidity (hospitalization, poor functional status, etc.)”
> “Four of the 8 individuals had a baseline ECOG score of 3, 1 had an ECOG of 2, and 3 had an ECOG of 1.”
> “Two individuals were under hospice consideration at baseline due to refractory hypoglycemia, progressive disease, and lack of remaining tumor-directed treatment options.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-2.2.1.8.1-3"></a>

### Impaired quality of life with residual hypoglycemia after insulinoma treatment (Japanese nationwide survey)

> “In addition, impaired quality of life was often reported in patients with residual hypoglycemia (9/29), which included persistent hypoglycemia requiring frequent snacks causing obesity or frequent hypoglycemic loss of consciousness.”

Source: [Yamada et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7232294/)

<a id="topic-2.2.1.8.1-4"></a>

### Long-term 15D health-related quality of life after curative surgery for insulinoma (Finland)

> “The HRQoL of adults diagnosed with an insulinoma in Finland in 1980-2010 was studied with the 15D instrument, and the results were compared to those of an age- and gender-matched sample of the general population.”
> “Thirty-eight insulinoma patients participated in the HRQoL survey (response rate 75%).”
> “All had undergone surgery with a curative aim, a median of 13 (min 7, max 34) years before the survey.”
> “The insulinoma patients had a clinically importantly and statistically significantly better mean 15D score compared with the controls (0.930 ± 0.072 vs 0.903 ± 0.039, P = .046) and were significantly better off regarding mobility, usual activities and eating.”
> “In the long term, the overall HRQoL of insulinoma patients is slightly better than that of the general population.”

Source: [Peltola et al. (2021a)](https://pubmed.ncbi.nlm.nih.gov/32974918/)

<a id="topic-2.2.1.8.1-5"></a>

### Health-related quality of life in non-islet cell tumor hypoglycemia

No evidence found.

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
